好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Plasma NF-L, tau, GFAP and advanced MRI imaging in the evaluation of mild Traumatic Brain Injury in a prospective cohort of active rugby players
Neuro Trauma, Critical Care, and Sports Neurology
P2 - Poster Session 2 (5:30 PM-6:30 PM)
4-057

To identify fluid biomarkers and brain imaging features associated with sport-related mild traumatic brain injury (mTBI).

The current approach to mTBI evaluation is heavily reliant upon symptom reporting and there is a need for objective tools to aid the process.

A prospective study of 220 active rugby players. We obtained baseline and post-mTBI plasma samples as well as neuro-psychometric assessments. Post-match players without mTBI were sampled as controls. Glial fibrillary acidic protein (GFAP), Neurofilament light (NF-L) and tau were measured using ultrasensitive single molecule array technology, the Simoa Human Neurology 4-Plex A assay. A subset of players (non-injured N=18 & post MTBI, N=10) underwent MRI brain imaging, including T1-volumetric, 99-direction multishell diffusion weighted and susceptibility weighted imaging (SWI). Non-rugby playing participants (N=32) were scanned as controls. Diffusion weighted images were pre-processed following the DTIFIT pipeline and fractional anisotropy (FA) values extracted.

We observed post-match elevations in NF-L, tau and GFAP. Tau was elevated in both post-match controls and post-match mTBI players, whereas NF-L and GFAP appeared to be specific for mTBI. NF-L and GFAP were elevated when measured between 1 hour and 10 days post injury. The presence of microbleeds on SWI were detected in 2/10 acute mTBI players and none in the controls. Mean FA showed significantly reduced FA within the right corticospinal tract across all rugby players.

GFAP and NF-L show potential as objective markers of brain injury in sport-related mTBI. The imaging results indicate that there may be effects of repetitive collisions on white matter integrity.

Authors/Disclosures
Etienne Laverse, MBBS, BSc, MRCP(Neurol), AICSM (Royal Surrey Hospital)
PRESENTER
Dr. Laverse has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
John A. Hardy, PhD (NIH/Lab of Neurogenetics/Institute on Aging) No disclosure on file
Henrik Zetterberg (Sahlgrenska University Hospital/Molndal) Henrik Zetterberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave. Henrik Zetterberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD. Henrik Zetterberg has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley and Elsevier. Henrik Zetterberg has stock in Brain Biomarker Solutions.
David J. Sharp, MD (Hammersmith Hospital) No disclosure on file
Huw R. Morris, MD, PhD Dr. Morris has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Morris has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aprinoia. Dr. Morris has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Morris has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Personal injury / Negligence cases. The institution of Dr. Morris has received research support from Parkinson's UK. The institution of Dr. Morris has received research support from Michael J Fox Foundartion. The institution of Dr. Morris has received research support from Cure Parkinson's Trust. The institution of Dr. Morris has received research support from PSP Association. The institution of Dr. Morris has received research support from CBD Solutions. The institution of Dr. Morris has received research support from Drake Foundation. The institution of Dr. Morris has received research support from Medical Research Council. Dr. Morris has received intellectual property interests from a discovery or technology relating to health care. Dr. Morris has a non-compensated relationship as a Scientific Advisory Board with Cure PSP that is relevant to AAN interests or activities. Dr. Morris has a non-compensated relationship as a Scientific Advisory Board with Parkinson's UK that is relevant to AAN interests or activities.